Market Place
Sourcing Support
Anokion Presents ANK-700 Data For Multiple Sclerosis
18 Sep 2024 //
BUSINESSWIRE
Alzheon To Present ALZ-801 Trial Results At Alzheimer`s Conference
23 Jul 2024 //
BUSINESSWIRE
Alzheon Raises $100M Series E For Alzheimer`s Drug Development
12 Jun 2024 //
BUSINESSWIRE
Alzheon Doses First Patient In APOLLOE4 Extension, Launches Phase 2
30 Apr 2024 //
BUSINESSWIRE
Alzheon’s oral anti-amyloid drug has to be first oral A?-targeting approved
18 Apr 2024 //
ECONOMICTIMES
Alzheon Announces that U.S. Patent Office Invalidating ALZ-801/Valiltramiprosate
08 Apr 2024 //
BUSINESSWIRE
Alzheon to Present Clinical Results from Pivotal Program of Oral ALZ-801
27 Feb 2024 //
BUSINESSWIRE
Alzheon Reports IClinical Benefits in Phase 2 Trial of Oral ALZ-801
13 Sep 2023 //
BUSINESSWIRE
Alzheon to Present Characteristics from APOLLOE4 Phase 3 Trial of ALZ-801
11 Jul 2023 //
BUSINESSWIRE
Alzheon Announces Early Completion of Enrollment of APOLLOE4 Phase 3 Trial
06 Dec 2022 //
BUSINESSWIRE
Alzheon Appoints Glenn Pauly as Head of Commercial
20 Sep 2022 //
FIRSTWORLDPHARMA
Alzheon Reports Brain Preservation for Treatment in PII Trial of ALZ-801
20 Sep 2022 //
BUSINESSWIRE
Alzheon`s Alzheimer`s asset axes brain injury biomarker in trial
20 Sep 2022 //
FIERCEBIOTECH
Alzheon to Present ALZ-801 Oral Tablet Program Update
07 Jun 2022 //
BUSINESSWIRE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.